TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34205744

Group type: EXPERIMENTAL
Intervention: mHealth application-based lifestyle coaching program
Number of subjects: 170
Study: 32086893

Group type: EXPERIMENTAL
Intervention: Mobile platform SCIT management
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional SCIT management
Number of subjects: 86
Study: 33166731

Group type: EXPERIMENTAL
Intervention: Osteoarthritis
Number of subjects: 320136
Study: 32534628

Group type: EXPERIMENTAL
Intervention: Adjuvanted AGS-v vaccine (200 nmol with Montanide ISA 51)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vaccine only AGS-v (200 nmol)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 49
Study: 36376023

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) pulse for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antiseizure medication (ASM) only
Number of subjects: 80
Study: 32192954

Group type: EXPERIMENTAL
Intervention: Low cost intervention (paying 1/3 unit deducts 1 unit of the allocator in Experiment 1)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: High cost intervention (paying 1 unit deducts 1 unit of the allocator in Experiment 2)
Number of subjects: 157
Study: 34404273

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention with a booster
Number of subjects: 596

Group type: COMPARATOR
Intervention: Control group (other brief alcohol interventions)
Number of subjects: 596
Study: 33986051

Group type: EXPERIMENTAL
Intervention: Stretch training on the 'five-Business' device, 22-24 training units of 10 minutes each, two times a week for 12 weeks.
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Stretch training on the 'five-Business' device
Number of subjects: 252
Study: 34030214

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) in addition to care-as-usual (CAU)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 103
Study: 36171019

Group type: COMPARATOR
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: mCPDAI
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAPSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: mCPDAI and DAPSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: All composites
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDA/VLDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: LDA
Number of subjects: 0
Study: 32367738

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) added to myo-inositol, alpha-lactalbumin, and folic acid in the evening from the early beginning of the luteal phase.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Myo-inositol, alpha-lactalbumin, and folic acid in the morning, and myo-inositol, folic acid and melatonin in the evening.
Number of subjects: 120
Study: 32176866

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 32199926

Group type: EXPERIMENTAL
Intervention: Routine prescription of 28 tablets of oxycodone 5 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Reduced prescription of 5 tablets of oxycodone 5 mg
Number of subjects: 118
Study: 36396066

Group type: EXPERIMENTAL
Intervention: Core intervention (booklet and personal report) + text messaging (on/off) + self-monitoring modality (digital/paper) + health coaching (on/off) + support person coaching (on/off)
Number of subjects: 400
Study: 33137600

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) then Behavioural Activation Therapy (BA) for MDD
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Behavioural Activation Therapy (BA) then Cognitive Processing Therapy (CPT)
Number of subjects: 52
Study: 35766588

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (diode laser 940 nm, 31.7 J/cm2 energy density, 1.7 cm2 spot size, 300 mW power, continuous-wave, contact mode)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soft acrylic wafer
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laser in off mode (placebo)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 28
Study: 32918555

Group type: EXPERIMENTAL
Intervention: Bone marrow stimulation (BMS)
Number of subjects: 60
Study: 32366992

Group type: EXPERIMENTAL
Intervention: Topical rifampicin irrigation
Number of subjects: 517

Group type: COMPARATOR
Intervention: Historical cohort (control)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Topical rifampicin
Number of subjects: 517
Study: 36384542

Group type: EXPERIMENTAL
Intervention: FPCR-BL (Flipped Physical Classroom Blended Learning)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: FVCR-BL (Flipped Virtual Classroom Blended Learning)
Number of subjects: 328

Group type: COMPARATOR
Intervention: PCR-TL (Traditional Learning Model in Physical Classroom)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: FPCR-BL
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Online learning
Number of subjects: 328
Study: 34113680

Group type: EXPERIMENTAL
Intervention: Family-centered social cognitive factors intervention
Number of subjects: 240
Study: 32012251

Group type: EXPERIMENTAL
Intervention: High-fat/calorie meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-fat/calorie meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 29
Study: 35139574

Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration the day after hCG triggering
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard treatment regime
Number of subjects: 267
Study: 34382648

Group type: EXPERIMENTAL
Intervention: Text-messaging intervention providing educational information and links to videos
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Text-messaging intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 32470531

Group type: EXPERIMENTAL
Intervention: EMI group
Number of subjects: 7860

Group type: EXPERIMENTAL
Intervention: PIS group
Number of subjects: 7860

Group type: EXPERIMENTAL
Intervention: Thrombectomy group with EMI
Number of subjects: 7860

Group type: COMPARATOR
Intervention: PCI alone group with EMI
Number of subjects: 7860

Group type: EXPERIMENTAL
Intervention: Thrombectomy group with PIS
Number of subjects: 7860

Group type: COMPARATOR
Intervention: PCI alone group with PIS
Number of subjects: 7860
Study: 34474432

Group type: EXPERIMENTAL
Intervention: Foam Rolling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vibration Foam Rolling
Number of subjects: 16
Study: 33487517

Group type: EXPERIMENTAL
Intervention: Vertical implementation strategy (all units trained simultaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Horizontal implementation strategy (one lead-off unit trained first)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both implementation strategies
Number of subjects: 0
Study: 33216113

Group type: EXPERIMENTAL
Intervention: Nebulized PC786 (5 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32757038

Group type: EXPERIMENTAL
Intervention: Rhino-Protect ointment
Number of subjects: 93
Study: 33189894

Group type: EXPERIMENTAL
Intervention: HI group performed 10 standing headers
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Leg impact group performed 10 soccer ball trapping maneuvers over 10 min
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group did not participate in any soccer drills
Number of subjects: 3
Study: 33371086

Group type: EXPERIMENTAL
Intervention: Continuous nursing treatment scheme based on Omaha system (OS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine treatment including general guidance associated with PD and outpatient telephone calls from clinical nurses
Number of subjects: 200
Study: 35590298

Group type: EXPERIMENTAL
Intervention: Magnification loupes (2.5×)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Participants with high visual acuity
Number of subjects: 59
Study: 33084903

Group type: EXPERIMENTAL
Intervention: Gutka usage (smokeless tobacco)
Number of subjects: 0
Study: 32160926

Group type: EXPERIMENTAL
Intervention: Met/Cys-low diet (n=7)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Met/Cys-high diet (n=6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Met/Cys-medium diet (n=7)
Number of subjects: 20
Study: 33839178

Group type: EXPERIMENTAL
Intervention: Lightwand
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fiberoptic bronchoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Glidescope
Number of subjects: 200
Study: 32537072

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 281
Study: 35511958

Group type: EXPERIMENTAL
Intervention: Disease Intervention Specialists (DIS) intervention for re-engagement in care
Number of subjects: 2958

Group type: COMPARATOR
Intervention: Non-randomized patients
Number of subjects: 2958
Study: 33554783

Group type: EXPERIMENTAL
Intervention: Run‐Hide‐Fight® video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to the video)
Number of subjects: 0
Study: 32243207

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 70
Study: 35241538

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Carboplatin AUC2 and Paclitaxel (45 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Switch from Cisplatin to Carboplatin/Paclitaxel
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Carboplatin/Paclitaxel
Number of subjects: 150
Study: 33662760

Group type: EXPERIMENTAL
Intervention: Cold water ingestion (COLD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinse (MENT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 32202020

Group type: EXPERIMENTAL
Intervention: High monocyte-to-lymphocyte ratio (MLR) >0.49
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: High lactate dehydrogenase (LDH)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Group 2 (MLR or LDH high)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Group 3 (MLR-LDH high)
Number of subjects: 528
Study: 35417442

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0
Study: 33068301

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg/day (n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100mg/day (n=40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional antidiabetic therapy (Control, n=40)
Number of subjects: 120
Study: 34421824

Group type: COMPARATOR
Intervention: Waist circumference (WC) ≥88 cm
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 2nd quartile
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 3rd quartile
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 4th quartile
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class I Obese
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class II Obese
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class III Obese
Number of subjects: 8887
Study: 32628781

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 39
Study: 36194619

Group type: EXPERIMENTAL
Intervention: Oral Qurs‐e‐Asfar (QA) 778 mg twice a day and topical Rogan‐e‐Narjeel (RN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Oral Itraconazole 100 mg/day and topical Terbinafine hydrochloride 1%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 32965622

Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3–4 times/week with symptomatic treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Symptomatic treatment only, no sexual intercourse or masturbation
Number of subjects: 70
Study: 32795778

Group type: EXPERIMENTAL
Intervention: 15-mg apomorphine sublingual film (APL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-mg subcutaneous Apo-go
Number of subjects: 0
Study: 35869885

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (9 motivational interviews in Year 1, followed by 3 sessions between Years 1 and 3)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1020
Study: 33786846

Group type: EXPERIMENTAL
Intervention: School-based intervention promoting physical activity and reducing sedentary time
Number of subjects: 0
Study: 32801193

Group type: EXPERIMENTAL
Intervention: Teleconference delivery of the Managing Fatigue intervention
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Internet delivery of the Managing Fatigue intervention
Number of subjects: 582

Group type: COMPARATOR
Intervention: In-person delivery of the Managing Fatigue intervention
Number of subjects: 582
Study: 35119481

Group type: EXPERIMENTAL
Intervention: Lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebos plus TACE
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab plus TACE
Number of subjects: 950
Study: 33530097

Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 385

Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 385
Study: 35667734

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) package including training in essential newborn care and QI tools
Number of subjects: 54919

Group type: COMPARATOR
Intervention: Control group (no QI package)
Number of subjects: 54919

Group type: EXPERIMENTAL
Intervention: Intervention group (with QI package)
Number of subjects: 54919
Study: 32616612

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 673
Study: 35087789

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 1641
Study: 35045888

Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in encapsulated form
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in suspension syrup form
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in throat spray form
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care with placebo
Number of subjects: 200
Study: 34327766

Group type: EXPERIMENTAL
Intervention: Modified capecitabine plus irinotecan (mXELIRI)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Fluorouracil, leucovorin, and irinotecan (FOLFIRI)
Number of subjects: 650
Study: 32682395

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine wound infusion by PCA pump
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline wound infusion by PCA pump (Control)
Number of subjects: 70
Study: 33756407

Group type: EXPERIMENTAL
Intervention: Treadmill walking for 20 minutes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group walking for 20 minutes on a treadmill
Number of subjects: 28
Study: 33022367

Group type: EXPERIMENTAL
Intervention: Telephonic intervention with a stepped protocol of 6–12 phone calls over 1 year, delivered by a health educator.
Number of subjects: 812

Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 812
Study: 34041935

Group type: EXPERIMENTAL
Intervention: Educational Intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 33
Study: 33886128

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 119
Study: 32072863

Group type: EXPERIMENTAL
Intervention: YouTube video with high perceived quality and popularity
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: YouTube video with low perceived quality and popularity
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Participants who conducted an online search
Number of subjects: 707
Study: 33433389

Group type: EXPERIMENTAL
Intervention: BF-CoCr stent
Number of subjects: 200

Group type: COMPARATOR
Intervention: BF-SS stent
Number of subjects: 200
Study: 33234646

Group type: EXPERIMENTAL
Intervention: MyCare intervention and standard mental health support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard mental health support
Number of subjects: 0
Study: 35724443

Group type: EXPERIMENTAL
Intervention: Probiotics intervention
Number of subjects: 37
Study: 33287790

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study: 36217640

Group type: EXPERIMENTAL
Intervention: AH Plus sealer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTA Fillapex sealer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GuttaFlow Bioseal sealer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silicone oil (used)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No silicone oil (not used)
Number of subjects: 60
Study: 34706172

Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg, subcutaneously once every 4 weeks)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 32705393

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo training (Sham) at 5% MIP for 4 weeks
Number of subjects: 14
Study: 33948911

Group type: EXPERIMENTAL
Intervention: Atogepant (60 mg) co-administered with Acetaminophen (1000 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atogepant (60 mg) co-administered with Naproxen (500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atogepant alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atogepant co-administered with Acetaminophen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atogepant co-administered with Naproxen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 40
Study: 32423038

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise with remote guidance (ME)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study: 34933308

Group type: EXPERIMENTAL
Intervention: Frame-based Gamma Knife radiosurgery
Number of subjects: 58

Group type: COMPARATOR
Intervention: Mask-based Gamma Knife radiosurgery
Number of subjects: 58
Study: 34384001

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Rosuvastatin (10 or 20 mg) SPC
Number of subjects: 125

Group type: COMPARATOR
Intervention: Telmisartan 80 mg monotherapy
Number of subjects: 125
Study: 32144515

Group type: EXPERIMENTAL
Intervention: Alvogyl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Absorbable gelatin sponge
Number of subjects: 36
Study: 35151285

Group type: EXPERIMENTAL
Intervention: CCT and Supported Employment (SE)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 116
Study: 33787645

Group type: EXPERIMENTAL
Intervention: Shen'ge formula (SGF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 32091599

Group type: EXPERIMENTAL
Intervention: Low-nitrate vegetables + placebo pills
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low-nitrate vegetables + nitrate pills (300 mg nitrate)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Leafy green vegetables containing 300 mg nitrate + placebo pills
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 243
Study: 33035741

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonstarters (compared to treatment starters)
Number of subjects: 200
Study: 36148513

Group type: EXPERIMENTAL
Intervention: Stroll Safe program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 86
Study: 34229085

Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation for 15 min before dressing (Lavender‐15 Group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation for 60 min before dressing (Lavender‐60 Group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control Group inhaled jojoba (placebo) oil for 15 min before dressing
Number of subjects: 108
Study: 34738961

Group type: EXPERIMENTAL
Intervention: Video debriefing with gaze overlay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video debriefing without gaze overlay
Number of subjects: 0
Study: 33143773

Group type: EXPERIMENTAL
Intervention: Chinese visceral adiposity index (CVAI) highest quartile
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Per-sd increase in CVAI
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Per-sd increase in CVAI change
Number of subjects: 10304

Group type: COMPARATOR
Intervention: CVAI compared to four other obesity indices
Number of subjects: 10304
Study: 32247297

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 47
Study: 34173078

Group type: EXPERIMENTAL
Intervention: Rotary system ProGlider and ProTaper Next X1, X2 (PG-PTN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reciprocating system WaveOne Gold Glider and WaveOne Gold Primary (WOGG-WOG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both systems (PG-PTN and WOGG-WOG)
Number of subjects: 30
Study: 34521298

Group type: EXPERIMENTAL
Intervention: Hugan tablets
Number of subjects: 623

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 623